Literature DB >> 14586889

Scope of worldwide hepatitis C problem.

Robert S Brown1, Paul J Gaglio.   

Abstract

1. Hepatitis C is a global health problem affecting over 170 million people worldwide. 2. There is wide geographic variation in both prevalence and genotype distribution of hepatitis C virus on a global level. 3. Most hepatitis C virus is spread parenterally, either through intravenous drug use or, in lesser-developed countries, through blood contamination during medical procedures. 4. Hepatitis C is a leading cause of end-stage liver disease and hepatocellular carcinoma. 5. Despite a declining incidence of new infections, the burden of disease, both in terms of mortality and in terms of cost, is expected to increase over the next decade.

Entities:  

Mesh:

Year:  2003        PMID: 14586889     DOI: 10.1053/jlts.2003.50244

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  41 in total

1.  The prevalence of hepatitis C virus infection in Texas: implications for future health care.

Authors:  Kanthi Yalamanchili; Sherif Saadeh; Rita Lepe; Gary L Davis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

2.  Hepatitis C and the surgeon.

Authors:  William D Fisher
Journal:  Can J Surg       Date:  2013-04       Impact factor: 2.089

3.  Structure-based simulations of the translocation mechanism of the hepatitis C virus NS3 helicase along single-stranded nucleic acid.

Authors:  Wenjun Zheng; Mustafa Tekpinar
Journal:  Biophys J       Date:  2012-09-19       Impact factor: 4.033

4.  Visualizing ATP-dependent RNA translocation by the NS3 helicase from HCV.

Authors:  Todd C Appleby; Robert Anderson; Olga Fedorova; Anna M Pyle; Ruth Wang; Xiaohong Liu; Katherine M Brendza; John R Somoza
Journal:  J Mol Biol       Date:  2010-12-09       Impact factor: 5.469

5.  SH2 modified STAT1 induces HLA-I expression and improves IFN-γ signaling in IFN-α resistant HCV replicon cells.

Authors:  Bret Poat; Sidhartha Hazari; Partha K Chandra; Feyza Gunduz; Luis A Balart; Xavier Alvarez; Srikanta Dash
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

Review 6.  Treatment of chronic hepatitis C in a slow responder: a case for extended therapy.

Authors:  Paul J Gaglio
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-06       Impact factor: 46.802

7.  UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication.

Authors:  Dawn N Ward; Daniel C Talley; Mrinalini Tavag; Samrawit Menji; Paul Schaughency; Andrea Baier; Paul J Smith
Journal:  Bioorg Med Chem Lett       Date:  2013-12-09       Impact factor: 2.823

8.  Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients.

Authors:  D B Clifford; M Smurzynski; L S Park; T-M Yeh; Y Zhao; L Blair; M Arens; S R Evans
Journal:  Neurology       Date:  2009-07-28       Impact factor: 9.910

Review 9.  Divergent contributions of regulatory T cells to the pathogenesis of chronic hepatitis C.

Authors:  Ayssa A Self; Phyllis T Losikoff; Stephen H Gregory
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

Review 10.  Clinical Use of Interferon-gamma.

Authors:  Catriona H T Miller; Stephen G Maher; Howard A Young
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.